Mauro Stocchi sold $293k of STVN
See Remarks at Stevanato Group S.p.A.. 13,649 shares at an average of $21.50, traded Sep 28, 2026, filed Sep 30, 2026.
Score components
- +15RoleOfficer
- +14Trade size$293k at market
- 0Share of holdings soldSold 3.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-409262, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | SOpen-market sale Ordinary Shares | -13,649 | $21.50 | $293k | 400,000 | 13 d ago |
Related signals
Other insiders at Stevanato Group S.p.A. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | STVNsell Stevanato Group S.p.A. | Lago Marco Dal Chief Financial Officer | $85k 4,209 shares | -5% | |
| 35Weak | Stevanato Group S.p.A. | Madhavan Balachandran director | $26k 1,493 shares | -2% | |
| 35Weak | Stevanato Group S.p.A. | William J Federici director | $26k 1,493 shares | -5% | |
| 40Moderate | Stevanato Group S.p.A. | Karen Flynn director | $26k 1,493 shares | -21% | |
| 35Weak | Stevanato Group S.p.A. | Donald E Morel Jr director | $26k 1,493 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.